EP3 receptor-mediated contraction of human pulmonary arteries and inhibition of neurogenic tachycardia in pithed rats

Pharmacological Reports

Volumn 64, Issue 6, 2012, Pages 1526-1536

  Kozłowska, Hanna ^a   Baranowska Kuczko, Marta ^a   Schlicker, Eberhard ^b   Kozłowski, Mirosław ^a   Zakrzeska, Agnieszka ^a   Grzȩda, Emilia ^a   Malinowska, Barbara ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Human pulmonary artery; L 826266; Neurogenic tachycardia; Pithed rats

Indexed keywords

ILOPROST; L 826266; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; SC 19920; SULOTROBAN; SULPROSTONE; UNCLASSIFIED DRUG;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; ELECTROSTIMULATION; FEMALE; HEART RATE; HUMAN; HUMAN TISSUE; MALE; NEUROGENIC TACHYCARDIA; NONHUMAN; PULMONARY ARTERY; RAT; TACHYCARDIA; VASOCONSTRICTION;

EID: 84873721606     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70950-7     Document Type: Article

References (36)

1. Alexander SPH, Mathie A, Peters JA: Guide to receptors and channels (GRAC), 5th edn. Br J Pharmacol, 2011, 164, Suppl 1, S1-S324.
2. Clark P, Rowland SE, Denis D, Mathieu MC, Stocco R, Poirier H, Burch J et al.: MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7- yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. J Pharmacol Exp Ther, 2008, 325, 425-434. (Pubitemid 351574801)
3. 2: Implication for cardiovascular grafts. Br J Pharmacol, 2011, 163, 826-834.
4. Gryglewski RJ, Mackiewicz Z: Vane's blood-bathed organ technique adapted to examine the endothelial effects of cardiovascular drugs in vivo. Pharmacol Rep, 2010, 62, 462-467.
5. 3 receptor antagonist L-826,266. Naunyn Schmiedeberg's Arch Pharmacol, 2010, 381, 21-31.
6. 2-induced constriction of porcine large cerebral arteries. J Cereb Blood Flow Metab, 2004, 24, 1305-1316.
7. 3 receptors in vasoconstrictor responses to isoprostanes in pulmonary vasculature. J Pharmacol Exp Ther, 2002, 301, 1060-1066.
8. Jones RL, Giembycz MA, Woodward DF: Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol, 2009, 158, 104-145.
9. 3-receptor in guinea-pig aorta: partial agonist action of the non-prostanoid ONO-AP-324. Br J Pharmacol, 1998, 125, 1288-1296.
10. Jones RL, Qian YM, Wong HNC, Chan H, Yim AP: Prostanoid action of the human pulmonary system. Clin Exp Pharmacol Physiol, 1997, 24, 969-972. (Pubitemid 27494310)
11. Jones RL, Woodward DF, Wang JW, Clark RL: Roles of affinity and lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth muscle preparations. Br J Pharmacol, 2011, 162, 863-879.
12. Juteau H, Gareau Y, Labelle M, Sturino CF, Sawyer N, Tremblay N, Lamontagne S et al.: Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor. Bioorg Med Chem, 2001, 9, 1977-1984. (Pubitemid 32739185)
13. 2 causes nociceptive behaviour and mechanical allodynia: the role of prostanoid E receptors and protein kinases. Br J Pharmacol, 2007, 150, 727-737.
14. nd edn. Raven Press Books Ltd., New York, 1993.
15. 3-I receptor isoform. Prostaglandins Leukot Essent Fatty Acids, 2007, 77, 195-201.
16. Kozłowska H, Baranowska M, Schlicker E, Kozłowski M, Laudański J, Malinowska B: Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. Br J Pharmacol, 2008, 155, 1034-1042.
17. 1-adrenoceptor mediated constriction in human pulmonary and rat mesenteric arteries. J Cardiovasc Pharmacol, 2005, 46, 76-82.
18. 3 receptor. Eur J Pharmacol, 2012, 681, 55-59.
19. 3 receptor-mediated inhibition of the neurogenic vasopressor response in pithed rats. Eur J Pharmacol, 1994, 259, 315-319.
20. 1 receptors. Naunyn-Schmiedeberg's Arch Pharmacol, 2001, 364, 233-241.
21. McCormick C, Jones RL, Kennedy S, Wadsworth RM: Activation of prostanoid EP receptors by prostacyclin analogues in rabbit iliac artery: implications for anti-restenotic potential. Eur J Pharmacol, 2010, 641, 160-167.
22. 3 receptors activates calcineurin and promotes hypertophy in the murine heart. Cardiovasc Res, 2009, 81, 310-318.
23. Molderings GJ, Colling E, Likungu J, Jakschik J, Göthert M: Modulation of noradrenaline release from the sympathetic nerves of the human saphenous vein and pulmonary artery by presynaptic EP3- and DP-receptors. Br J Pharmacol, 1994, 111, 733-738. (Pubitemid 24151658)
24. Molderings GJ, Likungu J, Göthert M: Modulation of noradrenaline release from the sympathetic nerves of the human right atrial appendages by presynaptic EP3- and DP-receptors. Naunyn-Schmiedeberg's Arch Pharmacol, 1998, 358, 440-444. (Pubitemid 28470841)
25. Moreland RB, Kim N, Nehra A, Goldstein I, Traish A: Functional prostaglandin E (EP) receptors in human penile corpus cavernosum. Int J Impot Res, 2003, 15, 362-368. (Pubitemid 37376942)
26. Norel X: Prostanoid receptors in the human vascular wall. ScientificWorld Journal, 2007, 7, 1359-1374.
27. 3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins Other Lipid Mediat, 2004, 74, 101-112.
28. Oliva P, Berrino L, de Novellis V, Palazzo E, Marabese I, Siniscalco S, Scafuro M et al.: Role of periaqueductal grey prostaglandin receptors in formalin-induced hyperglesia. Eur J Pharmacol, 2006, 530, 40-47. (Pubitemid 43037122)
29. 3-receptor agonists on human isolated pulmonary artery. Br J Pharmacol, 1994, 113, 369-374.
30. Stock A, Jones R, Chung T, Fung HY: Pulmonary edema in association with an intravenous infusion of sulprostone. Acta Obstet Gynecol Scand, 1995, 74, 156-158.
31. Sugimoto Y, Narumiya S: Prostaglandin E receptors. J Biol Chem, 2007, 282, 11613-11617. (Pubitemid 47100657)
32. 3-receptors reduce myocardial infarct size. A novel insight into cardioprotective effects of prostaglandins. Pharmacol Ther, 2000, 87, 61-67.
33. 3 receptor. Am J Physiol Renal Physiol, 2007, 292, F1094-F1101.
34. 1- and TP-receptors involved in the contraction of human pulmonary artery. Br J Pharmacol, 2001, 134, 1671-1678.
35. Woodward DF, Jones RL, Narumiya S: International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev, 2011, 63, 471-538.
36. Yuhki K, Kojima F, Kashiwagi H, Kawabe J, Fujino T, Narumiya S, Ushikubi F: Roles of prostanoids in the pathogenesis of cardiovascular diseases: Novel insights from knockout mouse studies. Pharmacol Ther, 2011, 129, 195-205.